CRTX 080 (Cornerstone) is filed at FDA for Hyponatraemia

FDA has accepted the new drug application for the investigational Hyponatraemia treatment CRTX 080, from Cornerstone Therapeutics CRTX 080 is a highly potent oral non-peptide, which acts on the vasopressin-2 receptor in the kidneys, causing water to be excreted while sparing sodium without affecting other electrolytes. Hyponatremia is a metabolic condition that occurs when there is not enough sodium in the blood and is the most common electrolyte disorder among hospitalized patients. It often is diagnosed in patients with heart failure, affecting about one-fourth of that population. The FDA is expected to make a decision by 29 October 2012